ACOSOG is a cooperative group comprised of practicing medical, radiation, and surgical oncologists, diagnostic imagers, patient advocates, pathologists, basic scientists, nurses/CRAs, statisticians, and other healthcare professionals representing academic and community practices throughout the U.S. The purpose of ACOSOG is to develop and evaluate innovative cancer therapies in which the surgical management of cancer patients plays a key role. ACOSOG Is dedicated to Improving the care of the surgical oncology patient through an Innovative clinical research program addressing three specific aims: 1. To test novel therapies that may increase response and cure rates and reduce morbidities and disabilities associated with cancer care 2. To conduct basic science studies in conjunction with clinical trials to better understand the biologic basis of diseases and treatments. 3. To support Individual members and investigator networks to accrue patients to trials and fulfill the scientific mission of ACOSOG. The scientific portfolio of ACOSOG is focused on investigations addressing three scientific aims for ACOSOG trials: 1) to investigate novel surgical and targeted therapies to maintain oncologic outcomes while reducing toxicities and disabilities and Improving quality of life;2) to enhance the accuracy of risk stratification through imaging and molecular profiling;and 3) to Improve overall response rates and monitor Individual responses through the application of neoadjuvant therapies. The scientific agenda is established by the Basic and Translational Science Committee and the three Disease Committees: Breast, Gastrointestinal (GIST, pancreas, and rectum), and Thoracic (lung and esophagus) and maintained and prioritized by the ACOSOG Peer Review Committees. A multidisciplinary approach to the scientific agenda is accomplished through the comprehensive integration of all modalities and disciplines. Membership interests, needs, and oversight are attended to through the actions of seven Administrative Committees. To accomplish the goals of ACOSOG, the group conducts clinical trials and correlative studies using an infrastructure consisting of three critical components Including: 1) the Operations and Membership Center (OMC) located in Durham, NC, within the Duke Clinical Research Institute;2) the Statistics and Data Center (SDC) located In Rochester, MN, within the Mayo Clinic Cancer Center;and 3) the Central Specimen Bank (U24 # 5 U24 CA114736) located in St. Louis, MO, within the Washington University.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA076001-17
Application #
8397546
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1998-05-15
Project End
2014-11-30
Budget Start
2012-12-01
Budget End
2014-11-30
Support Year
17
Fiscal Year
2013
Total Cost
$2,940,780
Indirect Cost
$366,279
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Foster, Jared C; Le-Rademacher, Jennifer G; Feliciano, Josephine L et al. (2017) Comparative ""nocebo effects"" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort. Cancer 123:4193-4198
Brown, Paul D; Ballman, Karla V; Cerhan, Jane H et al. (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CECĀ·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18:1049-1060
Churilla, Thomas M; Ballman, Karla V; Brown, Paul D et al. (2017) Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial. Int J Radiat Oncol Biol Phys 99:1173-1178
Ellis, Matthew J; Suman, Vera J; Hoog, Jeremy et al. (2017) Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol 35:1061-1069
Miller, Christopher A; Gindin, Yevgeniy; Lu, Charles et al. (2016) Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nat Commun 7:12498
Haffty, Bruce G; McCall, Linda M; Ballman, Karla V et al. (2016) Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance). Int J Radiat Oncol Biol Phys 94:493-502
Brown, Paul D; Jaeckle, Kurt; Ballman, Karla V et al. (2016) Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA 316:401-9
Kent, Michael S; Mandrekar, Sumithra J; Landreneau, Rodney et al. (2016) Impact of Sublobar Resection on Pulmonary Function: Long-Term Results from American College of Surgeons Oncology Group Z4032 (Alliance). Ann Thorac Surg 102:230-8
Boughey, Judy C; Ballman, Karla V; Le-Petross, Huong T et al. (2016) Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance) Ann Surg 263:802-7
Sikov, William M; Berry, Donald A; Perou, Charles M et al. (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (A J Clin Oncol 33:13-21

Showing the most recent 10 out of 65 publications